The need for new and better
antidepressants: reboxetine a new option

by
Dencker SJ
Neuropsychiatry Unit,
Institute of Clinical Neurosciences,
Sahlgrenska University Hospital,
Goteborg,
Sweden.
Acta Psychiatr Scand Suppl 2000; 402:6-11


ABSTRACT

The selective serotonin reuptake inhibitors (SSRIs) have obtained global attention but have not demonstrated superior efficacy in major depression compared with older tricyclic antidepressants. From a pharmacological viewpoint the noradrenergic system in the brain appears to have a central role in neurotransmitter organization. The importance of noradrenaline in depression is supported by its association with clinical parameters such as vigilance and drive. Reboxetine is a selective noradrenaline reuptake inhibitor--the first in its class to be marketed. In both preclinical and clinical studies reboxetine has been found to be an effective and safe antidepressant. Furthermore, reboxetine restores a patients' social functioning, producing a better quality of remission than fluoxetine.


Efficacy
Reboxetine
Noradrenaline
NARIs and SSRIs
Dopamine reuptake inhibition
Reboxetine and major depression
Reboxetine and social functioning
Depression, antidepressants and noradrenaline




Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family